linjc16/ctgov huggingface dataset:
Turkish Version of Telephone Based ABILOCO-Stroke

Study Overview
=================
Brief Summary
-----------------
The aims of this study were to perform cultural adaptation of the telephone based ABILOCO-stroke instrument and provide information regarding the factor structure, reliability and validity of the instrument in Turkish speaking patients with stroke.

Official Title
-----------------
Turkish Cultural Adaptation, Validation and Reliability Study of Telephone Based ABILOCO-Stroke

Conditions
-----------------
Stroke, Cultural Adaptation, Reliability, Validity

Intervention / Treatment
-----------------
* Other: Cultural adaptation, reliability and validity


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hemiparetic individuals who were ≥ 18 years of age were at least 4 weeks after the onset of the stroke able to walk with or without assistive devices. Exclusion Criteria: cognitive impairments aphasia any other non-stroke-related conditions.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of Telephone Based ABILOCO-Stroke|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Telephone Based ABILOCO-Stroke | ABILOCO is a measure of locomotion ability for adults with stroke survivors. | 10 minutes |
Assessment of MDD Management in Andalusia

Study Overview
=================
Brief Summary
-----------------
The main objectives of this study are to describe medical professionals responsible of the management of patients with MDD in a representative region of Andalusia (in terms of type of sites managing the disease, and referral to SC criteria); Describe MDD patient characteristics at inclusion in the PISMA-Ep Study; and to evaluate those factors associated to a higher incidence of referral from PC to SC.

Detailed Description
-----------------
Assessment of MDD management strategies in Andalusia: A Sub-analysis of the PismaEP Study

Official Title
-----------------
Assessment of MDD Management Strategies in Andalusia: A Sub-analysis of the PismaEP Study

Conditions
-----------------
MDD Management Strategies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: MDD Diagnosis Participants of the PismaEP study 18 yo. or older Exclusion Criteria: No specific exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Visits to Primary Care |  | From Jan 2010 to Jan 2011 | 
| Number of Visits to Secondary Care |  | From Jan 2010 to Jan 2011 | 
| Number of Referrals |  | From Jan 2010 to Jan 2011 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographics |  | From Jan 2010 to Jan 2011 | 
| Type of site |  | From Jan 2010 to Jan 2011 | 
| Type of therapeutic strategy |  | From Jan 2010 to Jan 2011 | 
| Type of disease |  | From Jan 2010 to Jan 2011 | 
| Severity of disease |  | From Jan 2010 to Jan 2011 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MDD, management, Andalusia, Database, PismaEP
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.

Official Title
-----------------
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

Conditions
-----------------
Involutional Osteoporosis

Intervention / Treatment
-----------------
* Drug: ONO-5920


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with fragility fracture according to the diagnostic criterial for the diagnosis of Primary Osteoporosis Patients having radiographically confirmed vertebral (T4-L4) fractures Other inclusion criteria as specified in the study protocol Exclusion Criteria: Patients having secondary osteoporosis or another condition that presents low bone mass Patients having findings on X-ray that affect evaluation of vertebral fracture Patients that have been administered bisphosphonate derivatives Other exclusion criteria as specified in the study protocol

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ONO-5920|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| New fragility vertebral fracture |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| New clinical fracture, biochemical markers of bone turnover, height, mean bone mineral density of the lumbar spoine (L2-4 BMD), lower back pain |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ONO-5920, osteoporosis, bisphosphonate
Incidence and Factors Associated With Double-J Urinary Stent Infection (IJJ)

Study Overview
=================
Brief Summary
-----------------
The aim of the study was to determine the incidence and factors associated with double-J urinary stent infection.

Official Title
-----------------
Incidence and Factors Associated With Double-J Urinary Stent Infection (IJJ)

Conditions
-----------------
Double J Stent

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a double-J stent placement or change in the hospital Exclusion Criteria: renal transplants less than one year old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Stent infection<br>Patients diagnosed with urinary tract infection associated with double J stent | |
| No stent infection<br>Patients with double J stent without infection during the study period | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with urinary tract infection associated with double J stent | Number of patients with urinary tract infection associated with double J stent | 6 months | 
| Number of patients with specific clinical data associated with urinary tract infection associated with double J stent | Clinical data (Age, sex, gender, comorbidities, indication of procedure, duration of double J stent placement) will be compared between patient with urinary tract infection and no urinary tract infection associated with double J stent | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with relapse and/or recurrence after a first urinary tract infection | Number of patients with relapse and/or recurrence after a first urinary tract infection | 6 months |
Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects

Study Overview
=================
Brief Summary
-----------------
Capturing the earliest stages of Dementia especially Alzheimer's Disease (AD) is a great challenge. Until now the NINCDS-ADRDA and the DSM criteria for AD were largely used as diagnostic standards in research. However, the research on AD progresses and some biomarkers have been recently suggested to improve the diagnostic criteria of AD, such as cerebrospinal fluid markers, neuroimaging with Positon Emission Tomography (PET) or Magnetic Resonance Imaging (MRI).

Official Title
-----------------
Estimation of Microstructure Alteration by MRI in Dementia Among Elderly Subjects Retired From Agricultural Profession and Living in Rural Area in Gironde - Participants From the AMI Cohort.

Conditions
-----------------
Dementia, Alzheimer Disease

Intervention / Treatment
-----------------
* Other: Neuroimaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: participate in the AMI cohort be aged 65 and older be retired from agricultural profession live in rural area in Gironde Exclusion Criteria: contraindication of MRI left-handed severe dementia Parkinson's disease poor health incompatible with the transport to neuroimaging service to be left handed

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| elderly subjects retired from agriculture<br> | Other: Neuroimaging<br>* Three successive MRI acquisitions to measure FA, MTR and T2 parameters.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FA (Fractional Anisotropy), MTR (magnetization transfer ratio) and T2 (Transverse relaxation time) measures in patients with dementia compared to controls, in left and right hippocampus, and posterior cingulum |  | day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FA, MTR and T2 measures in subjects with mild cognitive impairment no dementia |  | day 0 | 
| Performances in the 7 neuropsychological tests available in the AMI cohort |  | day 0 | 
| FA measures for the connexion Hippocampus-cingulum posterior |  | day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dementia, Alzheimer's Disease, diagnostic, biomarkers, neuroimaging, PET, MRI, mild cognitive impairment
Frequency of SARS COVID-19 Infection Among Malignant Patients at South Egypt Cancer Institute

Study Overview
=================
Brief Summary
-----------------
Assessment the frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute

Detailed Description
-----------------
Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus Most people infected with the virus will experience mild to moderate respiratory illness and recover without requiring special treatment. However, some will become seriously ill and require medical attention. Older people and those with underlying medical conditions like cardiovascular disease, diabetes, chronic respiratory disease, or cancer are more likely to develop serious illness. Anyone can get sick with COVID-19 and become seriously ill or die at any age Cancer is one of the most common examples of immunocompromised states

Official Title
-----------------
Frequency of SARS COV-2 Infection Among Malignant Patients at South Egypt Cancer Institute

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Other: disease


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Malignant patients. PCR positive for covid-19 Exclusion Criteria: PCR negative for covid-19

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: disease|Frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| calculate the frequency of SARS-CoV-2 infection among patients with malignant data collection during the study period | To calculate the rate of SARS-CoV-2 infection among patients with malignant data collection within covid-19 pandemic either retrospective or prospective. Data will include : patient demography such as Age,sex,smoking status,cancer type cancer treatment (patient on chemotherapy or radiotherapy if available), symptoms, signs and laboratory parameters of COVID -19. outcome including hospitalization or ICU admission and mortality rate will be recorded | 1 year |
Evaluation of the STOP-BANG Screening Questionnaire in a Sleep Clinic

Study Overview
=================
Brief Summary
-----------------
Although obstructive sleep apnea (OSA) is common, most of the patients are undiagnosed. OSA is associated with a large number of co-morbidities, and thus, it is of great importance to identify the patients and start treatment in order to reduce the risks for complications. Current screening tools are quite unspecific and the golden standard methodology for diagnosis, polysomnography, is expensive and time consuming, thus not suitable for screening. In perioperative medicine the STOP BANG screening questionnaire is currently the recomended screening tool, however this questionnaire has only been evaluated in a sleep clinic in a very limited numbers of patients.

Official Title
-----------------
Evaluation of the STOP-BANG Screening Questionnaire in a Sleep Clinic

Conditions
-----------------
Obstructive Sleep Apnea

Intervention / Treatment
-----------------
* Other: Obstructive sleep apnea


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: More than 18 years old First or part of the first visit to a sleep clinic Planned or just conducted polysomography Exclusion Criteria: Not able to understand the information and sign informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: STOP BANG<br>STOP BANG screening questionnaire and a snore question | Other: Obstructive sleep apnea<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| STOP BANG |  | At diagnosis, one time | 
| Snore question |  | At diagnosis, one time | 
| Polygraphy | Apnea hypopnea index (AHI, oxygen desatuaration index (ODI) | At diganosis, one time | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pulseoximetry |  | At dignosis, one time |
Study Evaluating MOA-728 Administered in Healthy Men

Study Overview
=================
Brief Summary
-----------------
Absorption, distribution, metabolism, and excretion (ADME) study with 14C in healthy young men.

Official Title
-----------------
An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]MOA-728 in Healthy Men

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: MOA-728


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men aged 18 to 50 years inclusive at screening. Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight ≥50 kg. BMI is calculated by taking the subject's weight, in kilograms, divided by the square of the subject's height, in meters, at screening: BMI = weight (kg)/[height (m)]2 Healthy as determined by the investigator on the basis of screening evaluations. Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to abstain from smoking during the inpatient stay.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MOA-728|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distribution of drug using radioactive study drug. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
healthy subjects
Comparison Between Two Types of Meshes Used in Pelvic Organs Prolapse Procedures

Study Overview
=================
Brief Summary
-----------------
Using partially absorbed meshes in pelvic reconstructive surgery will involve fewer postoperative complications especially less pain caused by the mesh mass.

Detailed Description
-----------------
Weakness of pelvic floor support is the cause defects and damage to pelvic organs functioning and urinary control and it has a pretty common occurrence. It was suggested recently that the event is considered a hernia that requires mesh use, which reduces return rates following pelvic floor repair. Mesh use is known to cause complications and unwanted side effects, such as chronic pain, vaginal network exposure and infection. The degree of complications is related directly to the mass of the mesh, and that's why the absorbable meshes were developed.Two months after the surgery with absorbable mesh, the mass left in the patient's body is half of the initial mesh mass and according to our assumption this effect will minimize the extent and intensity of mesh complications compared with conventional ones. During the study we will examine medical records of women who have had surgery with pelvic floor reconstructive meshes. The cases will be divided according to the mesh type being used. A polypropylene mesh (single strand and tunneling wide) trade name Prolift, and similar mesh that contains approximately half of the network mass after being dissolves in two months, a trade name Prolift + M. The number of participants in each group is 120 women. The post-operative follow-up examination will include three points in time. After a month, six months and a year later. In addition to questionnaires in order to quantify the degree of urinary disturbance, pain after surgery and sexual function.

Official Title
-----------------
Comparison Between Two Types of Meshes Used in Pelvic Organs Prolapse Procedures

Conditions
-----------------
Postoperative Complications

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women who had pelvic floor repair surgery wit mesh used to the posterior vaginal wall. Exclusion Criteria: Women with significant pre-operative pain Women with collagen diseases Women who underwent pelvic floor repair surgery with mesh to the anterior vaginal wall
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
absorbable mesh, Partially absorbed Mesh, Prolift, Prolift + M, mesh related complications
MK0524A Bioequivalence Study (0524A-059)

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the definitive bioequivalence of tablets of MK0524A (1000 mg Extended Release (ER) Niacin/ 20 mg laropiprant) from two sources.

Official Title
-----------------
An Open Label, Randomized, 2-Period, Crossover Study to Establish the Definitive Bioequivalence of Niacin and MK0524 of 2 Sources of MK0524A Tablets

Conditions
-----------------
Dyslipidemia

Intervention / Treatment
-----------------
* Drug: niacin (+) laropiprant (Source 1)
* Drug: Comparator: niacin (+) laropiprant (Source 2)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is in good health Subject is willing to follow all study guidelines Exclusion Criteria: Subject has or has a history of any disease or condition that might confound the results of the study or make participation unsafe

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A<br>MK0524A Source 1 (Phase III manufacturing site) | Drug: niacin (+) laropiprant (Source 1)<br>* Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 1 in one of two treatment periods.<br>|
| Active Comparator: B<br>MK0524A Source 2 (commercial manufacturing site) | Drug: Comparator: niacin (+) laropiprant (Source 2)<br>* Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 2 in one of two treatment periods.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum Plasma Concentration (Cmax) of Nicotinuric Acid | Measure of rate of absorption of ER niacin | Predose and up to 24 hours postdose | 
| Total Amount of Urinary Excretion of Niacin and Its Metabolites | Measure of extent of absorption of ER niacin | Predose and up to 96 hours postdose | 
| Area Under Curve (AUC 0-infinity) of Laropiprant | Measure of extent of absorption of laropiprant | Predose and up to 48 hours postdose | 
| Maximum Concentration (Cmax) of Laropiprant | Measure of rate of absorption of laropiprant | Predose and up to 48 hours postdose |